Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427478 | 1.00 | MEN1 (0.43) | MEN1KMT2AUSP2CTSKLMNA | |
| SCHEMBL5092584 | 0.91 | CTSK (0.47) | MEN1KMT2ACTSKLMNAGAA | |
| SCHEMBL5096573 | 0.91 | EPHX2 (0.42) | MEN1KMT2ACTSKLMNACTSL | |
| SCHEMBL4767024 | 0.91 | MEN1 (0.40) | MEN1KMT2AUSP2CTSKLMNA | |
| SCHEMBL7434825 | 0.90 | KMT2A (0.45) | MEN1KMT2ACTSKGAA | |
| SCHEMBL5093139 | 0.90 | KMT2A (0.45) | MEN1KMT2ACTSKGAA | |
| SCHEMBL7431349 | 0.89 | KMT2A (0.45) | MEN1KMT2ACTSKLMNAGAA | |
| SCHEMBL6628532 | 0.86 | CTSK (0.43) | MEN1KMT2ACTSKLMNAGAA | |
| SCHEMBL7427486 | 0.83 | MEN1 (0.47) | MEN1KMT2AUSP2CTSKLMNA | |
| SCHEMBL5099617 | 0.83 | CTSK (0.42) | CTSKGAACTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |